Related Experiment Video
Updated: Mar 8, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.8K
Hypersensitivity to ticagrelor and low response to clopidogrel: a case report
Jing Dai1, Shuzheng Lyu1, Changjiang Ge1
1Department of Cardiology, Capital Medical University Affiliated to Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing 100029, China.
Asia Pacific Allergy
|February 4, 2017
Summary
Managing patients with acute coronary syndrome who have both a poor response to clopidogrel and ticagrelor hypersensitivity is challenging. This case study demonstrates successful antithrombotic therapy using aspirin and warfarin.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Ticagrelor is a common treatment for acute coronary syndrome.
- Low response to clopidogrel affects up to 23% of patients and increases stent thrombosis risk.
- Ticagrelor hypersensitivity is a rare but significant concern.
Observation:
- A patient presented with both a documented low response to clopidogrel and hypersensitivity to ticagrelor.
- Standard antiplatelet therapy options were limited due to these conditions.
Findings:
- The patient was successfully managed with a combination of aspirin and warfarin for antithrombotic therapy.
- This alternative regimen provided effective anticoagulation and antiplatelet coverage.
Implications:
- This case highlights a viable alternative treatment strategy for patients with complex antiplatelet therapy challenges.
- It suggests that a combination of aspirin and warfarin can be considered in select cases of ticagrelor hypersensitivity and clopidogrel non-response.
- Further research may explore the safety and efficacy of this regimen in similar patient populations.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
76
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
01:16Drug toxicity: Idiosyncratic Reactions
84
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
84
01:24Drug Toxicity: Risk factors
66
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
66
01:20Desensitization and Tachyphylaxis
3.3K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.3K
01:01Hypersensitivity Reactions: Cytolytic Reactions
81
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
81